Dasatinib: an inhibitor of tyrosine kinase (ITK) effective in acute transformations of CML and in Ph

被引：0
|
作者：
Rousselot, Philippe
机构：
来源：
HEMATOLOGIE | 2007年 / 13卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：282 / 283
页数：3
相关论文
共 50 条
  • [41] Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
    Haznedaroglu, Ibrahim C.
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2014, 6 (01)
  • [42] NSCLC: Amivantamab effective in Patients with Tyrosine Kinase Inhibitor Resistance
    Metzger, Leandra
    PNEUMOLOGIE, 2022, 76 (04):
  • [43] Detection of mutations in CML patients resistant to tyrosine kinase inhibitor: imatinib mesylate therapy
    Nilgun Karasu
    Hilal Akalin
    Nuriye Gokce
    Abdulbaki Yildirim
    Mikail Demir
    Hande Kulak
    Serhat Celik
    Muzaffer Keklik
    Munis Dundar
    Medical Oncology, 2021, 38
  • [44] The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients
    Putri, Anastasia
    Rinaldi, Ikhwan
    Louisa, Melva
    Koesnoe, Soekamto
    ACTA MEDICA INDONESIANA, 2019, 51 (04) : 348 - 352
  • [45] Detection of mutations in CML patients resistant to tyrosine kinase inhibitor: imatinib mesylate therapy
    Karasu, Nilgun
    Akalin, Hilal
    Gokce, Nuriye
    Yildirim, Abdulbaki
    Demir, Mikail
    Kulak, Hande
    Celik, Serhat
    Keklik, Muzaffer
    Dundar, Munis
    MEDICAL ONCOLOGY, 2021, 38 (10)
  • [46] Growth inhibition of Ph+ progenitor cells from CML patients using the tyrosine kinase inhibitor CGP57148B
    Waller, CF
    Ali, M
    Heinzinger, M
    Lange, W
    ANTICANCER RESEARCH, 2000, 20 (2A) : 809 - 814
  • [47] Interaction of the chemotherapeutic agent oxaliplatin and the tyrosine kinase inhibitor dasatinib with the organic cation transporter 2
    Eltayeb, Sara
    Dressler, Julia M.
    Schlatt, Lukas
    Pernecker, Moritz
    Neugebauer, Ute
    Karst, Uwe
    Ciarimboli, Giuliano
    ARCHIVES OF TOXICOLOGY, 2024, 98 (07) : 2131 - 2142
  • [48] Stable Fatty Acid Solvates of Dasatinib, a Tyrosine Kinase Inhibitor: Prediction, Process, and Physicochemical Properties
    Saladi, Venkata Narasayya
    Kammari, Bal Raju
    Maruthapillai, Arthanareeswari
    Mahapatra, Sudarshan
    Chennuru, Ramanaiah
    Sajja, Eswaraiah
    Rajan, Srinivasan Thirumalai
    Mathad, Vijayavitthal T.
    ACS OMEGA, 2022, 7 (08): : 7032 - 7044
  • [49] Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
    Mustjoki, S.
    Ekblom, M.
    Arstila, T. P.
    Dybedal, I.
    Epling-Burnette, P. K.
    Guilhot, F.
    Hjorth-Hansen, H.
    Hoglund, M.
    Kovanen, P.
    Laurinolli, T.
    Liesveld, J.
    Paquette, R.
    Pinilla-Ibarz, J.
    Rauhala, A.
    Shah, N.
    Simonsson, B.
    Sinisalo, M.
    Steegmann, J. L.
    Stenke, L.
    Porkka, K.
    LEUKEMIA, 2009, 23 (08) : 1398 - 1405
  • [50] The tyrosine kinase inhibitor dasatinib effectively blocks PDGF-induced orbital fibroblast activation
    Sita Virakul
    Virgil A. S. H. Dalm
    Dion Paridaens
    Willem A. van den Bosch
    Nattiya Hirankarn
    P. Martin van Hagen
    Willem A. Dik
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2014, 252 : 1101 - 1109
12345